195 related articles for article (PubMed ID: 21952275)
1. Therapeutic cancer vaccine development: will it ride the wave of new immunomodulatory agents?
Eggermont AM
Cancer J; 2011; 17(5):276. PubMed ID: 21952275
[No Abstract] [Full Text] [Related]
2. Cancer immunotherapy.
White RL; Amin A
Surg Oncol Clin N Am; 2011 Jul; 20(3):531-54, ix. PubMed ID: 21640920
[TBL] [Abstract][Full Text] [Related]
3. [Current status and future perspective of cancer immunotherapy--clinical application and development].
Aruga A
Nihon Geka Gakkai Zasshi; 2013 Nov; 114(6):327-31. PubMed ID: 24358730
[No Abstract] [Full Text] [Related]
4. Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy.
Baxevanis CN; Perez SA; Papamichail M
Cancer Immunol Immunother; 2009 Mar; 58(3):317-24. PubMed ID: 18704409
[TBL] [Abstract][Full Text] [Related]
5. [New era of tumor immunotherapy].
Yoshitake Y; Nakatsura T; Nishimura Y
Nihon Rinsho; 2005 Apr; 63 Suppl 4():46-55. PubMed ID: 15861634
[No Abstract] [Full Text] [Related]
6. New checkpoint inhibitors ride the immunotherapy tsunami.
Mullard A
Nat Rev Drug Discov; 2013 Jul; 12(7):489-92. PubMed ID: 23812256
[No Abstract] [Full Text] [Related]
7. [Not Available].
Ostendorf GM
Versicherungsmedizin; 2016 Mar; 68(1):31-3. PubMed ID: 27111958
[No Abstract] [Full Text] [Related]
8. New approaches to immunoprevention and immunotherapy of neoplasms.
Glushkov AN
Russ J Immunol; 2002 Oct; 7(3):219-28. PubMed ID: 12674931
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic cancer vaccines.
Ward S; Dalgleish A
Vaccine; 2007 Sep; 25 Suppl 2():B1-3. PubMed ID: 17681649
[No Abstract] [Full Text] [Related]
10. Cancer immunotherapy.
Schuster M; Nechansky A; Kircheis R
Biotechnol J; 2006 Feb; 1(2):138-47. PubMed ID: 16892244
[TBL] [Abstract][Full Text] [Related]
11. New perspectives in cancer immunotherapy and immunomonitoring.
Umansky V; Malyguine A; Shurin M
Future Oncol; 2009 Sep; 5(7):941-4. PubMed ID: 19792962
[No Abstract] [Full Text] [Related]
12. [Immunological tumor therapy].
Dietrich K; Theobald M
Internist (Berl); 2015 Aug; 56(8):907-16; quiz 917. PubMed ID: 26187335
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal antibodies in cancer immunotherapy.
Kimiz-Gebologlu I; Gulce-Iz S; Biray-Avci C
Mol Biol Rep; 2018 Dec; 45(6):2935-2940. PubMed ID: 30311129
[TBL] [Abstract][Full Text] [Related]
14. The anti-idiotype vaccines for immunotherapy.
Bhattacharya-Chatterjee M; Chatterjee SK; Foon KA
Curr Opin Mol Ther; 2001 Feb; 3(1):63-9. PubMed ID: 11249733
[TBL] [Abstract][Full Text] [Related]
15. Are mimotope vaccines a good alternative to monoclonal antibodies?
Pourjafar M; Samadi P; Khoshinani HM; Saidijam M
Immunotherapy; 2019 Jun; 11(9):795-800. PubMed ID: 31094256
[TBL] [Abstract][Full Text] [Related]
16. Tumor-specific antigens and immunologic adjuvants in cancer immunotherapy.
Seremet T; Brasseur F; Coulie PG
Cancer J; 2011; 17(5):325-30. PubMed ID: 21952282
[TBL] [Abstract][Full Text] [Related]
17. Cancer immunotherapy: a treatment for the masses.
Blattman JN; Greenberg PD
Science; 2004 Jul; 305(5681):200-5. PubMed ID: 15247469
[TBL] [Abstract][Full Text] [Related]
18. [Current status and future perspective of cancer vaccine development].
Sasada T; Itoh K
Gan To Kagaku Ryoho; 2011 Apr; 38(4):503-8. PubMed ID: 21498975
[TBL] [Abstract][Full Text] [Related]
19. Anti-ErbB-2 monoclonal antibodies and ErbB-2-directed vaccines.
Yip YL; Ward RL
Cancer Immunol Immunother; 2002 Jan; 50(11):569-87. PubMed ID: 11807621
[TBL] [Abstract][Full Text] [Related]
20. From therapeutic monoclonal antibodies to therapeutic vaccines for cancer.
Berinstein NL
Hum Vaccin; 2009 Jun; 5(6):364-7. PubMed ID: 19694082
[No Abstract] [Full Text] [Related]
[Next] [New Search]
